Company newsMRNA
Explain this story: Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.
Moderna's stock surged 7% following investor optimism surrounding its personalized cancer vaccine, intismeran autogene, ahead of Phase 3 melanoma data presentation at ESMO on October 24. Despite the jump, the stock's current price of $195 significantly surpasses the average analyst target of $120. CEO Stéphane Bancel also reframed Moderna as an mRNA platform company, focusing on oncology and rare diseases, rather than solely a COVID-19 vaccine developer.
OtherYahoo FinanceSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Moderna's stock surged 7% following investor optimism surrounding its personalized cancer vaccine, intismeran autogene, ahead of Phase 3 melanoma data presentation at ESMO on October 24. Despite the jump, the stock's current price of $195 significantly surpasses the average analyst target of $120. CEO Stéphane Bancel also reframed Moderna as an mRNA platform company, focusing on oncology and rare diseases, rather than solely a COVID-19 vaccine developer.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:MRK